Kenyon represented Teva Pharmaceuticals in these litigations brought by Sanofi-Aventis in the New Jersey District Court on Sanofi-Aventis's Allegra® antihistamine product. In early 2006, The Court denied Sanofi-Aventis's motion for a preliminary injunction, thereby allowing Teva to remain on the market with a generic version of Allegra®. The market for Allegra® was $1.5 billion at the time Teva launched its product. Teva, Aventis and AMR settled the ongoing litigations between them concerning Allegra® in late 2008. Case number 2:04-cv-01078 (2008).